MPM Oncology Impact Management »

Syndax Pharmaceuticals shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Syndax Pharmaceuticals (SNDX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Syndax Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Syndax Pharmaceuticals held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Syndax Pharmaceuticals by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $21M 1.4M 15.39

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Syndax Pharmaceuticals

BlackRock
Kynam Capital Management
Goldman Sachs Group
Vanguard Group
Point72 Asset Management
State Street Corporation
Eversept Partners
Adage Capital Partners GP
Kingdon Capital Management
Franklin Resources
Geode Capital Management
Soleus Capital Management
Assenagon Asset Management
UBS Group
Qube Research & Technologies

View all funds holding Syndax Pharmaceuticals